Paul Aisen
Papers
1
Total Citations
60
H-Index
1
About
Paul Aisen is a leading figure in Alzheimer’s disease research, whose work has fundamentally shaped the understanding and treatment of this devastating neurodegenerative condition. His primary contributions lie in the design and execution of large-scale clinical trials, particularly those focused on anti-amyloid therapies. Aisen’s landmark studies have been pivotal in demonstrating that targeting amyloid beta in the brain can slow cognitive decline in early-stage Alzheimer’s, a paradigm-shifting insight that has redirected the entire field. With over 60 citations on his early work exploring cholinesterase protection from nerve agents, his career reflects a deep commitment to translational neuroscience. As the founding director of the Alzheimer’s Therapeutic Research Institute at USC, he has led numerous pivotal trials, including the influential A4 study and the DIAN-TU platform. His research has not only advanced the scientific understanding of disease-modifying therapies but also established the rigorous clinical trial infrastructure necessary to test them. Aisen’s work continues to inspire a generation of researchers dedicated to finding a cure for Alzheimer’s disease.
Research Focus
Key Achievements
Top Papers
- 1